Andrew Okun Sells 2,324 Shares of PerkinElmer, Inc. (PKI) Stock

PerkinElmer, Inc. (NYSE:PKI) insider Andrew Okun sold 2,324 shares of the business’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $75.44, for a total transaction of $175,322.56. Following the transaction, the insider now directly owns 8,876 shares in the company, valued at $669,605.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Andrew Okun also recently made the following trade(s):

  • On Monday, February 5th, Andrew Okun sold 2,273 shares of PerkinElmer stock. The stock was sold at an average price of $77.86, for a total transaction of $176,975.78.
  • On Friday, December 15th, Andrew Okun sold 12,680 shares of PerkinElmer stock. The stock was sold at an average price of $72.00, for a total transaction of $912,960.00.

PerkinElmer, Inc. (PKI) traded up $0.77 on Friday, reaching $72.83. 1,212,966 shares of the company traded hands, compared to its average volume of 769,324. The firm has a market capitalization of $8,351.76, a PE ratio of 25.95, a PEG ratio of 1.75 and a beta of 0.76. The company has a quick ratio of 0.90, a current ratio of 1.27 and a debt-to-equity ratio of 0.72. PerkinElmer, Inc. has a 1 year low of $53.63 and a 1 year high of $84.49.

PerkinElmer (NYSE:PKI) last posted its quarterly earnings results on Thursday, January 25th. The medical research company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.03. The firm had revenue of $641.63 million for the quarter, compared to analysts’ expectations of $619.14 million. PerkinElmer had a net margin of 12.97% and a return on equity of 13.30%. The firm’s quarterly revenue was up 13.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.83 earnings per share. sell-side analysts predict that PerkinElmer, Inc. will post 3.52 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 10th. Investors of record on Friday, April 13th will be issued a $0.07 dividend. The ex-dividend date is Thursday, April 12th. This represents a $0.28 annualized dividend and a yield of 0.38%. PerkinElmer’s dividend payout ratio is presently 10.61%.

Institutional investors and hedge funds have recently bought and sold shares of the stock. State of Wisconsin Investment Board bought a new stake in PerkinElmer during the third quarter valued at $1,673,000. Bessemer Group Inc. increased its stake in PerkinElmer by 22.2% during the third quarter. Bessemer Group Inc. now owns 27,149 shares of the medical research company’s stock valued at $1,873,000 after purchasing an additional 4,936 shares during the last quarter. Sivik Global Healthcare LLC increased its stake in PerkinElmer by 12.5% during the third quarter. Sivik Global Healthcare LLC now owns 90,000 shares of the medical research company’s stock valued at $6,207,000 after purchasing an additional 10,000 shares during the last quarter. King Luther Capital Management Corp increased its stake in PerkinElmer by 1.3% during the third quarter. King Luther Capital Management Corp now owns 2,562,833 shares of the medical research company’s stock valued at $176,759,000 after purchasing an additional 32,248 shares during the last quarter. Finally, Toronto Dominion Bank increased its stake in PerkinElmer by 26.4% during the second quarter. Toronto Dominion Bank now owns 35,925 shares of the medical research company’s stock valued at $2,447,000 after purchasing an additional 7,505 shares during the last quarter. 90.98% of the stock is currently owned by hedge funds and other institutional investors.

PKI has been the topic of a number of recent research reports. Robert W. Baird reissued a “buy” rating and set a $88.00 target price on shares of PerkinElmer in a research report on Friday, January 26th. Zacks Investment Research raised shares of PerkinElmer from a “hold” rating to a “buy” rating and set a $86.00 target price on the stock in a research report on Monday, January 8th. Cowen reissued a “hold” rating and set a $84.00 target price on shares of PerkinElmer in a research report on Friday, January 26th. Jefferies Group reissued a “hold” rating and set a $70.00 target price on shares of PerkinElmer in a research report on Friday, October 20th. Finally, ValuEngine cut shares of PerkinElmer from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $76.85.

ILLEGAL ACTIVITY WARNING: “Andrew Okun Sells 2,324 Shares of PerkinElmer, Inc. (PKI) Stock” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://sportsperspectives.com/2018/02/09/andrew-okun-sells-2324-shares-of-perkinelmer-inc-pki-stock.html.

PerkinElmer Company Profile

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Insider Buying and Selling by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply